



For Immediate Release
May11, 2016

SUNSHINE BIOPHARMA SIGNS LICENSING AGREEMENT FOR ANASTROZOLE, THE COMPANY'S FIRST GENERIC DRUG FOR TREATMENT OF BREAST CANCER

Montreal, Quebec – (MARKETWIRE) – Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, is pleased to announce that it has signed a Cross Referencing Agreement with a major pharmaceutical company for Anastrozole, a prescription generic drug for treatment of Breast Cancer. Sunshine will market and sell this new pharmaceutical product under its own label.

Sunshine is currently in the process of securing a Drug Identification Number (“DIN”) for its own label of Anastrozole from Health Canada. The Company is also working on obtaining a Drug Establishment License (“DEL”) from Health Canada. Upon receipt of the DIN, Sunshine will be able to accept orders for its SBI-Anastrozole. Sunshine expects to build a portfolio of “SBI” label Generic Pharmaceuticals over time.

Revenues from the sale of Generic Products are intended to be used to finance the Company's proprietary drug development program including Adva-27a, the Company's flagship anticancer compound. A Topoisomerase II inhibitor, Adva-27a is a small molecule that has recently been shown to be effective at destroying Multidrug Resistant Breast Cancer cells, Pancreatic Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Number 8,236,935.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:

Sunshine Biopharma Inc.

Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com